PREMARIN® (conjugated estrogens) Vaginal Cream 0.5 g has been approved by the U.S. Food and Drug Administration (FDA) for a new indication and a new less frequent twice-weekly dosing regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual intercourse) announced Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE). (PRWeb Nov 13, 2008)
Read the full story at http://www.prweb.com/releases/vaginal_cream/premarin_vaginal/prweb1614152.htm
